These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 25222580)

  • 1. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C; Rutkowski P; Brzuszkiewicz K; Bylina E; Limon J; Siedlecki JA
    Pol Przegl Chir; 2014 Jul; 86(7):325-32. PubMed ID: 25222580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
    Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
    Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
    Qi C; Pan F; Li J; Li Y; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
    Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
    Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
    Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 9. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 11. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
    Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
    Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
    Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
    Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
    Lee JH; Kim Y; Choi JW; Kim YS
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
    Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
    Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
    He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extra-gastrointestinal stromal tumor arising in the lesser omentum with a platelet-derived growth factor receptor alpha (PDGFRA) mutation: a case report and literature review.
    Kanamori K; Yamagata Y; Honma Y; Date K; Wada T; Hayashi T; Otsuki S; Sekine S; Yoshikawa T; Katai H; Nishida T
    World J Surg Oncol; 2020 Jul; 18(1):183. PubMed ID: 32703220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
    Reichardt P; Reichardt A
    Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.